Gerresheimer stock eases after recent gains as sustainability rating improves

Published on 09/18/2026 at 12:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gerresheimer stock closed at EUR 27.40 on Xetra on September 17, 2026, leaving the shares about 14 percent below a cited 52-week high near EUR 32.00. The health care packaging specialist recently secured EcoVadis Gold status again, underpinning its sustainability profile.

Flatlay mit Aktienzertifikat, ISIN-Karte, Glasampullen und Spritze — Gerresheimer AG, ISIN DE000A0LD6E6, symbolisiert durch Flatlay-Arrangement aus Aktienzertifikat, ISIN-Karte und pharmazeutischen Glasampullen, Illustration mit AI erstellt.

Gerresheimer stock (ISIN DE000A0LD6E6) closed at EUR 27.40 on Xetra on September 17, 2026, down about 0.94% from the previous session, keeping the health care packaging specialist below the EUR 30 mark after a strong recovery from its 2026 lows per price data from Xetra and market portals.

Sustainability rating supports investor narrative

According to Gerresheimer in a sustainability news update published on September 17, 2026, the company has once again been awarded EcoVadis Gold status, reflecting strong performance in areas such as environment, labor and human rights, ethics and sustainable procurement.

This renewed EcoVadis Gold rating provides a qualitative counterweight to the recent share price consolidation, as investors in the health care and pharmaceutical supply chain increasingly factor sustainability assessments into long term portfolio decisions.

Share performance and 52-week range

Per Xetra based price data cited in recent market coverage, Gerresheimer shares closed at EUR 28.92 on September 15, 2026, with the stock trading between about EUR 27.12 at the intraday low and roughly EUR 28.30 at the high on that day, before easing back to EUR 27.40 by the close on September 17, 2026.

The same coverage referenced a 2026 low near EUR 14.83 and a year high around EUR 32.00, indicating that at the September 15, 2026 close of EUR 28.92 the stock had risen by roughly 95% from the low while still standing about 9.6% below the cited high, a profile that combines substantial recovery with remaining upside and corresponding downside risk.

Valuation context and fair value indications

An overview from Investing.com shows Gerresheimer quoted around EUR 27.17 in real time on September 18, 2026, corresponding to a modest intraday decline of roughly 0.98%, which fits the picture of a stock consolidating after strong earlier gains.

In a separate valuation oriented update, Simply Wall St recently adjusted its fair value estimate for Gerresheimer from EUR 25.26 to EUR 27.38, an increase of approximately 8.36%, and noted that at a referenced market price of EUR 27.66 the shares were about 1.0% above this intrinsic value marker, suggesting only a slight premium to that particular fundamental model.

Stock price level and market capitalization

Based on the September 15, 2026 Xetra closing price of EUR 28.92 and the cited market capitalization of around EUR 920,000,000, investors can infer that Gerresheimer sits in the mid cap range of the German equity market, with the valuation reflecting both its role as a key supplier to pharmaceutical and health care clients and the market’s assessment of its growth and margin prospects.

At the more recent close of EUR 27.40 on September 17, 2026, the shares traded noticeably below the psychologically important EUR 29 threshold mentioned in earlier coverage, underscoring that the stock has given back part of its short term gains but remains well above the 2026 lows as of mid September 2026.

Closing price snapshot

Gerresheimer stock last closed at EUR 27.40 on Xetra on September 17, 2026, with the session reflecting a daily loss of about 0.94% and placing the shares roughly 14% below the cited 52-week high around EUR 32.00 while still trading significantly above the 2026 low near EUR 14.83.